Press Releases
Principal IRB Becomes Univo IRB With Support From QHP Capital
Today, Univo IRB was announced as the new company
name for Principal IRB. Univo IRB is a next generation institutional review
board (IRB) recently acquired by QHP Capital, an investment manager exclusively
focused on building and supporting tech-enabled life sciences and pharma
services companies. Univo IRB is focused on full-scale IRB services, bringing
decades of IRB and clinical operations experience to support today’s clinical
trials.
At last week’s SCOPE Summit in
Orlando, Florida, Univo IRB shared its plans to bring the voice of patients
closer to research by creating an agile and efficient IRB review experience.
This experience can only be achieved by combining Univo’s highly proficient
workforce consisting of IRB members and staff who have hands-on research
experience and industry-first technologies that are purpose-built for today’s
complex trials. Univo IRB maintains accreditation through the Association for
the Accreditation of Human Research Protection Programs (AAHRPP), which
consists of a federally regulated IRB committee charged with protecting the
rights and welfare of people in research.
“The IRB sector has seen
significant consolidation as firms vie to remain competitive in the face of
economic, regulatory, and societal challenges affecting research review and
oversight; however, most IRB’s have become too big and bureaucratic, limiting
their agility and ability to service customers and patients in today’s modern
research environment,” said Univo IRB President Julie Blasingim. “At Univo, we do not want
to be biggest IRB, but we are clearly focused on being the best! We welcome you to experience the best and witness our
commitment to highly qualified IRB reviews with fast turnarounds and
exceptional customer experience.”
“Univo IRB is committed to reviving
the IRB industry’s focus on principles of human research protection, unifying
patients and research,” said Michael Sorensen, Partner at QHP Capital.
“We remain committed to supporting this team of IRB experts and the company as
it launches the modern iteration of IRB solutions and grows to support the next
generation of clinical trials.”
About Univo
IRB
Univo IRB, formerly Principal IRB, is a
next generation institutional review board (IRB) specializing in the ethical
review of Phase I-IV pharmaceutical, device, biologic, behavioral, and
psycho-social research. We offer agile study approaches, expert solutions powered
by industry-leading study technology, and a service-first approach. Univo IRB
holds accreditation through the Association for the Accreditation of Human
Research Protection Programs (AAHRPP). With support from senior advisors and
60+ years of industry experience, Univo IRB guides your study to approval while
respecting the rights and welfare of patients every step of the way.
About QHP Capital
QHP Capital, L.P. invests in lower middle
market healthcare companies primarily in North America, with a focus on
services and technology companies where a strategic partner and operating
resources can accelerate growth. Targeting companies in healthcare and
pharmaceutical services industries, QHP invests in the form of buyouts, growth
equity, and recapitalizations.